The Patent Finder

Terms ending in 2032

Yeda Research and Development Co. Ltd.

Every in-force patent on Yeda Research and Development Co. Ltd.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,365,828Genetically Modified Muscle Cells Which Express Neurotrophic Factors
In force
 · High confidence
Yeda Research and Development Co. Ltd.In forceHigh confidence
US 10,744,162Genetically Modified Muscle Cells Which Express Neurotrophic Factors
In force
 · Medium confidence
Ramot at Tel-Aviv University Ltd.In forceMedium confidence
US 9,067,052Magnetic Configuration and Timing Scheme for Transcranial Magnetic Stimulation
In force
 · High confidence
Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceIn forceHigh confidence
US 11,491,301Device and Method for Controlling Respiration During Sleep
In force
 · Medium confidence
Yeda Research and Development Co. Ltd.In forceMedium confidence
US 10,288,622Use of Akt Phosphorylation as a Biomarker for Prognosing Neurodegenerative Diseases and Treating Same
In force
 · Medium confidence
Yeda Research and Development Co. Ltd.In forceMedium confidence
US 9,623,049Immunotherapy Using Redirected Allogeneic Cells
In force
 · High confidence
Yeda Research and Development Co. Ltd.In forceHigh confidence
US 9,150,858Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions
In force
 · High confidence
Yeda Research and Development Co. Ltd.In forceHigh confidence
US 9,901,593Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions
In force
 · Medium confidence
Yeda Research and Development Co. Ltd.In forceMedium confidence
US 10,238,681Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions
In force
 · Medium confidence
Yeda Research and Development Co. Ltd.In forceMedium confidence
US 12,016,876Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions
In force
 · Medium confidence
Yeda Research and Development Co. Ltd.In forceMedium confidence
9 more term ends in 2032 · Pro
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
Upgrade to Pro
17 of these are in force and held by Yeda Research and Development Co. Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited